Overview
Gallstone dissolution agents are pharmaceutical compounds designed to dissolve cholesterol-based gallstones in patients who are not suitable candidates for surgical intervention. The two primary agents used are ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA). These agents work by altering the composition of bile, reducing cholesterol secretion, and promoting the gradual dissolution of gallstones. They are typically prescribed for small, non-calcified gallstones in patients with a functioning gallbladder. These agents are particularly valuable for elderly patients or those with comorbidities that increase surgical risks. Treatment duration can range from several months to years, depending on stone size and patient response. Regular monitoring via ultrasound is essential to assess efficacy.
Physical and Chemical Properties
UDCA and CDCA are bile acids with similar molecular structures but differing in their stereochemistry. Both are white to off-white crystalline powders, soluble in organic solvents like ethanol but only slightly soluble in water. UDCA has a melting point of 200-204°C, while CDCA melts at 165-167°C. These compounds are stable under recommended storage conditions but degrade when exposed to excessive heat or moisture. The efficacy of these agents depends on their ability to reduce cholesterol saturation in bile. UDCA is generally better tolerated than CDCA, with fewer gastrointestinal side effects. Both agents are metabolized in the liver and excreted in bile, making them suitable for long-term use in patients with preserved liver function.
Main Applications
Gallstone dissolution agents are primarily used to treat cholesterol gallstones in patients who cannot undergo cholecystectomy. They are most effective for small (less than 15mm), non-calcified stones in a functioning gallbladder. UDCA is also used to treat primary biliary cholangitis and other cholestatic liver diseases due to its hepatoprotective effects. In clinical practice, these agents are often prescribed for patients with asymptomatic or mildly symptomatic gallstones. They are not recommended for pigment stones or calcified cholesterol stones, as these are resistant to dissolution. Combination therapy with CDCA and UDCA is sometimes employed to enhance efficacy while minimizing side effects.
Safety and Storage
Gallstone dissolution agents are generally safe but can cause side effects such as diarrhea, abdominal discomfort, and elevated liver enzymes. CDCA is more likely to cause diarrhea than UDCA. Both agents are contraindicated in pregnancy due to potential fetal harm and in patients with severe liver disease. Proper storage is essential to maintain the stability of these compounds. They should be kept in a cool, dry place, away from direct light and moisture. Bulk procurement for hospitals or pharmacies should ensure proper packaging and transportation to prevent degradation. Expired or improperly stored medications should not be used, as their efficacy may be compromised.
B2B Procurement Guide
When sourcing gallstone dissolution agents, B2B buyers should prioritize suppliers with pharmaceutical-grade certifications and compliance with Good Manufacturing Practices (GMP). Key considerations include purity (typically ≥98%), packaging (blister packs or bottles with desiccants), and batch-to-batch consistency. Pricing varies based on dosage strength and quantity, with bulk orders often qualifying for discounts. Buyers should verify the supplier's track record, regulatory approvals, and ability to provide certificates of analysis. For international procurement, ensure compliance with import regulations and consider lead times for shipping and customs clearance.
Related Manufacturers
- 主营：胆酸、半叶素、二羟基吲哚、缩合剂、表面活性剂、硅烷偶联剂、生物缓冲液、L-丙交酯、光电材料中间体、精细化工
- 主营：6-二羟基吲哚、二羟基吲哚啉氢溴酸、水解角蛋白、化学试剂级别、7-去氢胆固醇、石胆酸钠盐、熊去氧胆酸钠盐、2-辛基十二醇、2-巯基噻唑啉、2-巯基苯并咪唑、苯基周位酸(8-苯胺、L-丙交酯、半叶素、乙烯利、环丙磺酰胺、苄氧基胺盐酸盐、1-氨基环丙烷羧酸、4-联苯甲醇丙烯酸酯、4-羟乙烯基氧基二苯、咪鲜胺、可比落、乙交酯、D(+)-丙交酯
- 主营：5-二甲基吡唑、N-油酰基肌氨酸、环己基苯、β-溴苯乙烷、乙基纤维素、硫酸烟酰苯胺、2-辛烯基琥珀酸酐、菜籽油甲酯、5二硝基水杨酸、辛酸镁、辛酸钾、有机硅季铵盐、萘钠处理液
- 主营：杀菌剂